Stay updated on Apremilast-Dupilumab Combo in Eczema Clinical Trial
Sign up to get notified when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.

Latest updates to the Apremilast-Dupilumab Combo in Eczema Clinical Trial page
- Check7 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check43 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page now displays Revision: v3.4.2. The funding-status notice has been removed (the previous Revision: v3.4.1 was deleted).SummaryDifference0.5%

- Check79 days agoChange DetectedAdded a funding-status notice at the top of the page about potential data currency issues and a Revision banner showing v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check86 days agoChange DetectedAdded a glossary display option and updated labeling for QC-related items (Last Update Submitted that Met QC Criteria; No FEAR Act Data) with a revision notice (Revision: v3.4.0), replacing the previous variants (Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Apremilast-Dupilumab Combo in Eczema Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.